Syndax revenue rises 92% to $72.8 million in Q2; net loss narrows
Syndax Pharmaceuticals reported second-quarter 2026 total revenue of $72.8 million, up 92% from a year earlier, driven by $54.7 million in Revuforj net revenue and $18.1 million in Niktimvo collaboration revenue. The quarterly net loss narrowed to $49.4 million, or $0.55 per share, from $71.8 million, or $0.83 per share, a year earlier, and the company continues to expect 2026 research and development plus selling, general and administrative expenses of about $400 million, excluding about $50 million of non-cash stock compensation.
Key points
- Total revenue of $72.8 million in Q2 2026 versus $38.0 million in Q2 2025.
- Revuforj net revenue of $54.7 million, up 91% year over year; Niktimvo net revenue of $60.3 million, with Syndax's collaboration revenue at $18.1 million.
- Quarterly net loss of $49.4 million, or $0.55 per share, compared with $71.8 million, or $0.83 per share, in Q2 2025.
- Cash, cash equivalents and investments were $575.1 million as of June 30, 2026; Phase 2 axatilimab topline data in IPF and frontline cGVHD are expected in Q4 2026.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.